Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

Real-time Euronext Paris 15:14:05 03/06/2024 BST 5-day change 1st Jan Change
90.33 EUR +0.64% Intraday chart for Sanofi +0.47% +0.58%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
DHL Strikes Logistics Partnership with Sanofi MT
SANOFI : Gets a Neutral rating from JP Morgan ZD
GSK shares tumble 9% after 70,000 Zantac lawsuits allowed to proceed RE
Sanofi Enlists Banks for EUR20 Billion Consumer Health Spinoff, IPO MT
GSK Plans Appeal Against US Judge's Ruling on Jury Trials for Zantac Cases MT
Sanofi Moving Ahead With EUR20Bln Consumer Healthcare Spinoff, FT Reports DJ
Sanofi Enlists Banks for EUR20 Billion Consumer Health Spinoff, IPO MT
Delaware judge lets more than 70,000 Zantac lawsuits go forward RE
CAC40: at the 8000 pts threshold, loses nearly 1.3% over the week CF
CAC40: remains at equilibrium despite sharp decline in Nasdaq and S&P CF
CAC40: May ends with no trend and a zero score CF
EMA backs approving Sanofi's Dupixent for 'smoker's lungs', FDA extends review RE
Sanofi, Regeneron's Dupixent Receives Recommendation for Approval From European Medicines Agency Committee MT
Sanofi: launch of employee share ownership plan 2024 CF
CAC40: stable trend before US inflation CF
Regeneron Pharmaceuticals, Sanofi Say Dupixent FDA Application Decision Delayed by 3 Months MT
Sanofi: positive opinion from the CHMP in COPD CF
CAC40: slightly positive bias before the opening CF
US FDA Delays Decision on Sanofi, Regeneron's Lung Disease Treatment Dupixent MT
Sanofi, Regeneron's Lung Disease Treatment Recommended for EU Approval MT
Sanofi's Dupixent Drug Review Date Extended by Three Months in the U.S. DJ
Regeneron Pharmaceuticals, Inc and Sanofi Announce Dupixent® Recommends for EU Approval by the CHMP to Treat Patients with COPD CI
Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® for the Treatment of COPD Patients with Type 2 Inflammation CI
CAC40: regains some altitude, Airbus in support CF
Sanofi Closes Purchase of US Biotech Company Inhibrx MT
Chart Sanofi
More charts
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
89.76 EUR
Average target price
108.2 EUR
Spread / Average Target
+20.53%
Consensus
  1. Stock Market
  2. Equities
  3. SAN Stock
  4. News Sanofi
  5. Sanofi Teams Up with Formation Bio, OpenAI for Drug Development AI Software
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW